Gemcitabine as a radiosensitizer in undifferentiated tumors.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Anticancer Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 16475690
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.

  2003cited by this paper
• Selective targeting of homologous DNA recombination repair by gemcitabine.

  2003cited by this paper
• Response to motexafin gadolinium and ionizing radiation of experimental rat prostate and lung tumors.

  2003cited by this paper
• Effect of gemcitabine on acute and late radiation toxicity of skin and underlying soft tissues to single-dose irradiation in a nude mice model.

  2002cited by this paper
• Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule.

  2002cited by this paper
• Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.

  2002cited by this paper
• Angiostatin gene therapy inhibits the growth of murine squamous cell carcinoma in vivo.

  2001cited by this paper
• Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma 1

  2001cited by this paper
• End-joining deficiency and radiosensitization induced by gemcitabine.

  2001cited by this paper
• Combined use of gemcitabine and radiation in mice.

  2001cited by this paper
• Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).

  2000cited by this paper
• Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants

  2000cited by this paper
• Homologous and non‐homologous recombination differentially affect DNA damage repair in mice

  2000cited by this paper
• Enhancement of tumor radioresponse in vivo by gemcitabine.

  1999cited by this paper
• The XRCC2 and XRCC3 repair genes are required for chromosome stability in mammalian cells.

  1999cited by this paper
• Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination

  1999cited by this paper
• XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.

  1999cited by this paper
• Effect of gemcitabine on the tolerance of the lung to single-dose irradiation in C3H mice.

  1999cited by this paper
• Maximizing therapeutic gain with gemcitabine and fractionated radiation.

  1999cited by this paper
• The Drosophila melanogaster DmRAD54 Gene Plays a Crucial Role in Double-Strand Break Repair after P-Element Excision and Acts Synergistically with Ku70 in the Repair of X-Ray Damage

  1999cited by this paper
• The XRCC2 DNA repair gene from human and mouse encodes a novel member of the recA/RAD51 family

  1998cited by this paper
• Homologous recombination and non‐homologous end‐joining pathways of DNA double‐strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells

  1998cited by this paper
• Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro.

  1998cited by this paper
• XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages.

  1998cited by this paper
• Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model.

  1997cited by this paper
• The XRCC2 DNA repair gene: identification of a positional candidate.

  1997cited by this paper
• Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.

  1997cited by this paper
• Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination.

  1997cited by this paper
• Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine.

  1996cited by this paper
• Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

  1995cited by this paper
• Preclinical characteristics of gemcitabine

  1995cited by this paper
• Growth rate, morphology and drug responses of rat lung tumours growing at different sites.

  1994cited by this paper
• Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas.

  1994cited by this paper
• Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.

  1994cited by this paper
• Cytokeratins expressed in experimental rat bronchial carcinomas

  1993cited by this paper
• Response to chemotherapy of non-small cell bronchial rat tumours growing subcutaneously or in the lung.

  1991cited by this paper
• Synergistic Antitumor Effects of Rat γ-Interferon and Human Tumor Necrosis Factor α against Androgen-dependent and -independent Rat Prostatic Tumors

  1991cited by this paper
• Synergistic antitumor effects of rat gamma-interferon and human tumor necrosis factor alpha against androgen-dependent and -independent rat prostatic tumors.

  1991cited by this paper
• 2′,2′-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells

  1989cited by this paper
• A Chinese hamster ovary cell line hypersensitive to ionizing radiation and deficient in repair replication.

  1988cited by this paper
• Isolation and cross-sensitivity of X-ray-sensitive mutants of V79-4 hamster cells.

  1987cited by this paper
• Characterization of a new primary human pancreatic tumor line.

  1986cited by this paper
• Human pancreatic carcinoma (mia paca‐2) in continuous culture: Sensitivity to asparaginase

  1977cited by this paper

• The Role of Oxygen in Avascular Tumor Growth

  2016cites this paper
• Cyclopentenyl cytosine has biological and anti-tumour activity, but does not enhance the efficacy of gemcitabine and radiation in two animal tumour models.

  2009cites this paper
• Treatment of stage III non-small cell lung cancer and limited-disease small-cell lung cancer

  2009cites this paper
• Cytotoxic drugs sensitize tumor cells to immune cell-mediated killing by interleukin-2 activated peripheral blood leukocytes

  2007cites this paper